NO314222B1 - Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype - Google Patents

Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype Download PDF

Info

Publication number
NO314222B1
NO314222B1 NO19911690A NO911690A NO314222B1 NO 314222 B1 NO314222 B1 NO 314222B1 NO 19911690 A NO19911690 A NO 19911690A NO 911690 A NO911690 A NO 911690A NO 314222 B1 NO314222 B1 NO 314222B1
Authority
NO
Norway
Prior art keywords
gene
cells
retinoblastoma
cancer
protein
Prior art date
Application number
NO19911690A
Other languages
English (en)
Norwegian (no)
Other versions
NO911690L (no
NO911690D0 (no
Inventor
Wen-Hwa Lee
Huei-Jen Su Huang
Eva Y H P Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO314222(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of NO911690D0 publication Critical patent/NO911690D0/no
Publication of NO911690L publication Critical patent/NO911690L/no
Publication of NO314222B1 publication Critical patent/NO314222B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19911690A 1988-10-31 1991-04-29 Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype NO314222B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26582988A 1988-10-31 1988-10-31
PCT/US1989/004808 WO1990005180A1 (en) 1988-10-31 1989-10-30 Products and methods for controlling the suppression of the neoplastic phenotype

Publications (3)

Publication Number Publication Date
NO911690D0 NO911690D0 (no) 1991-04-29
NO911690L NO911690L (no) 1991-06-25
NO314222B1 true NO314222B1 (no) 2003-02-17

Family

ID=23012037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19911690A NO314222B1 (no) 1988-10-31 1991-04-29 Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype

Country Status (9)

Country Link
EP (2) EP0792931A3 (de)
JP (1) JPH03505675A (de)
AT (1) ATE161039T1 (de)
AU (3) AU638954B2 (de)
CA (1) CA2001815C (de)
DE (1) DE68928491T2 (de)
FI (1) FI113377B (de)
NO (1) NO314222B1 (de)
WO (1) WO1990005180A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US7105156B1 (en) 1987-09-17 2006-09-12 The Regents Of The University Of California Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
KR970005049B1 (ko) * 1990-07-16 1997-04-11 더 리젠츠 오브 더 유니벌시티 오브 캘리포니아 바쿨로비루스 발현 시스템, 이 벡터 시스템을 포함하는 이종성 무척추동물 숙주세포, 상기 시스템에 의해 생산되는 가용성의 정제된 야생형 망막아세포종 폴리펩티드 및 이 폴리펩티드의 생산 방법
US5569824A (en) * 1991-01-04 1996-10-29 Baylor College Of Medicine Transgenic mice containing a disrupted p53 gene
AU1366992A (en) * 1991-01-16 1992-08-27 Cancer Institute, The Inherited and somatic mutations of apc gene in colorectal cancer of humans
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU663702B2 (en) 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5330892A (en) * 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
TW346397B (en) 1991-10-17 1998-12-01 Univ California Cell cycle controlling compositions and methods of using same
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
CA2206205A1 (en) * 1994-11-28 1996-06-06 Genetic Therapy, Inc. Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
TR200001125T2 (tr) * 1997-10-25 2000-09-21 Roche Diagnostics Gmbh Retro virüs vektörleri için sübye paketleme hücre sıraları.
FR2843526A1 (fr) * 2002-08-16 2004-02-20 Inst Nat Sante Rech Med Utilisation d'animaux heterozygotes cdx2+/-pour tester des factures cancerogenes ou anti-cancereux
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4942123A (en) * 1987-09-17 1990-07-17 The Regents Of The University Of California ppRB110 -phosphoprotein the retinoblastoma susceptibility gene product

Also Published As

Publication number Publication date
NO911690L (no) 1991-06-25
AU670624B2 (en) 1996-07-25
AU4635089A (en) 1990-05-28
AU7042196A (en) 1997-02-20
NO911690D0 (no) 1991-04-29
FI911997A0 (fi) 1991-04-25
EP0440744B1 (de) 1997-12-10
EP0792931A2 (de) 1997-09-03
EP0440744A1 (de) 1991-08-14
FI113377B (fi) 2004-04-15
WO1990005180A1 (en) 1990-05-17
AU638954B2 (en) 1993-07-15
EP0440744A4 (en) 1992-07-01
DE68928491D1 (de) 1998-01-22
DE68928491T2 (de) 1998-06-04
EP0792931A3 (de) 1999-05-19
ATE161039T1 (de) 1997-12-15
AU4915593A (en) 1994-01-13
JPH03505675A (ja) 1991-12-12
CA2001815C (en) 2002-09-03
CA2001815A1 (en) 1990-04-30

Similar Documents

Publication Publication Date Title
EP0440744B1 (de) Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
Ireton et al. A novel role for p120 catenin in E-cadherin function
DK2081586T3 (en) RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES
JPH11500614A (ja) 多重腫瘍異常生長遺伝子
EP2298878A2 (de) Zusammensetzungen und verfahren zur krebsdiagnose
Sánchez‐Sánchez et al. Attenuation of disease phenotype through alternative translation initiation in low‐penetrance retinoblastoma
Islam et al. Molecular cloning, characterization, and chromosomal localization of a human lymphoid tyrosine kinase related to murine Blk.
Fazioli et al. A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma
US5858771A (en) Products and methods for controlling the suppression of the neoplastic phenotype
WO2020143424A1 (zh) 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
US20140234321A1 (en) Hunk, a snf1-related kinase essential for mammary tumor metastasis
US20020132340A1 (en) Isogenic beta-catenin cell lines, and methods of making and using same
US7060688B2 (en) Products and methods for controlling the suppression of the neoplastic phenotype
US7507801B2 (en) Adapter gene
NZ507787A (en) Novel mutations in the FREAC3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis
US9079938B2 (en) ASPP2 splicing variant
JP5093578B2 (ja) 受容体型プロテインチロシンホスファターゼＰｔｐｒｚによるＥｒｂＢ４シグナルの抑制
US20170334966A1 (en) Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer
EP1163335A1 (de) Werkstoffen und verfahren zur modulierung der p66 expression
JP2002530349A (ja) Ｎｆ−ａｔ媒介の心臓肥大、それに関係する方法及び試薬
Neill Protein interactions mediated by the product of the tumour suppressor gene N eurofibromatosis type II
Symonds Cellular targets of papovaviral T antigens in tumorigenesis
Sampson David J Kwiatkowski, Mary Pat Reeve, Jeremy P Cheadle and
Mantere DNA damage response gene mutations and inherited susceptibility to breast cancer
Sitwala Transcriptional and post-translational mechanisms controlling the pattern of DEK expression